Byron Donalds Selects Two Stocks: AI and Obesity Treatment as 'Hot Themes'

Republican Representative Byron Donalds disclosed in a May 13 filing that on April 2 he purchased one share each of Eli Lilly and Company (LLY), a leader in obesity and diabetes treatments, and Marvell Technology, Inc. (MRVL), a prominent AI semiconductor firm. According to the filing, each transaction was valued between $1,001 and $15,000. Both stocks have continued to rally since the trades, raising questions about advance thematic positioning.

Donalds, who represents Florida’s 19th District, serves on the House Financial Services Committee and the Oversight Committee. Within those panels, he sits on subcommittees covering digital assets, fintech, artificial intelligence, financial institutions, economic growth, energy policy, health care, and financial services. A longtime critic of the Affordable Care Act—calling it “an attempt by the government to seize control of health care”—he has consistently advocated for deregulation and market-based medical reform, repeatedly opposing drug-price negotiation legislation and limits on pharmaceutical profits. His personal investments in a major drugmaker and an AI chip company add fuel to the ongoing bipartisan debate over a proposed ban on congressional stock trading.

Eli Lilly’s first-quarter 2026 revenue rose 56% year-over-year to $19.8 billion, driven by its GLP-1 obesity and diabetes drugs Mounjaro and Zepbound, prompting the company to raise its full-year guidance. Since April 2, when LLY traded around $936, the shares have climbed about 7% to just over $1,000. Several Wall Street analysts have upped their price targets to $1,400, citing long-term growth prospects in obesity treatment. The concern is that Donalds, who leads hearings on health-care costs and drug pricing in the Health and Financial Services Subcommittee, also stands to benefit from a company dependent on high-margin obesity drugs. As debates over price cuts, insurance-coverage adjustments, and expanded Medicare negotiation rights intensify, the public may question whether his oversight activity serves constituents or his personal portfolio.

Marvell Technology, which specializes in high-speed networking and interconnect chips for data centers and the cloud, saw its stock surge after Nvidia announced in early April a $2 billion strategic investment and an NVLink-based AI infrastructure partnership. MRVL shares, trading near $110 in early April, have jumped nearly 60% to the mid-$170s in about a month, amid growing expectations for AI data-center investment and higher valuation-driven volatility. As a member of the Financial Services Committee’s Digital Assets, Fintech, and AI Subcommittee—where discussions focus on market information asymmetry and AI-infrastructure regulation—Donalds’s participation in this rally creates a clear conflict of interest. While he met his disclosure obligations under the STOCK Act, the intensifying push to ban congressional stock trading means these purchases, though legal, pose significant political and ethical risks.